Workflow
If I Could Only Buy 3 Stocks in the Last Month of 2024, I'd Pick These
IOVAIovance Biotherapeutics(IOVA) The Motley Fool·2024-12-19 09:02

Group 1: Investment Opportunities - The article highlights three stocks that are considered attractive investment opportunities before the end of 2024, particularly as they are currently priced at a discount from their highs [2][3]. Group 2: The Coca-Cola Company - The Coca-Cola Company has experienced a 1% decline in drink sales compared to the same quarter last year, leading to a 14% drop in stock price from its peak in September [3][4]. - Despite recent challenges, Coca-Cola is viewed as a steady grower with a reliable earnings engine, having raised its annual dividend for 62 consecutive years [5][6]. - The company's market dominance and brand recognition contribute to its long-term success, making the recent stock decline an attractive buying opportunity [6]. Group 3: Uber Technologies - Uber Technologies reported 161 million rides last quarter, generating 11.2billioninrevenue,markingayearoveryearincreaseof1311.2 billion in revenue, marking a year-over-year increase of 13% and 22% respectively [7][8]. - Analysts project Uber's revenue to grow by 17% this year and nearly 16% next year, with the global ride-hailing market expected to grow over 11% annually through 2032 [9][10]. - The company is now consistently profitable, with earnings per share expected to rise from 0.87 last year to 1.89thisyear,andfurtherto1.89 this year, and further to 2.31 next year [10][11]. Group 4: Iovance Biotherapeutics - Iovance Biotherapeutics is a biopharma company with its flagship drug, Amtagvi, recently receiving FDA approval, although its stock has declined over 50% since the approval [12][14]. - Expected revenue for Iovance is projected to be between 160millionand160 million and 165 million for the current fiscal year, with growth anticipated to reach 450millionto450 million to 475 million next year [15]. - The company is on track to potentially achieve profitability by 2027, with ongoing trials for Amtagvi indicating a possibility of exceeding $1 billion in annual revenue by 2030 [16].